Literature DB >> 33905096

Commentary to Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.

Agata Buonacera1, Benedetta Stancanelli1, Lorenzo Malatino2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33905096     DOI： 10.1007/s40292-021-00455-9

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN： 1120-9879


× No keyword cloud information.
  9 in total

1.  The reverse remodeling response to sacubitril/valsartan therapy in heart failure with reduced ejection fraction.

Authors:  Pieter Martens; Hanne Beliën; Matthias Dupont; Pieter Vandervoort; Wilfried Mullens
Journal:  Cardiovasc Ther       Date:  2018-06-07       Impact factor: 3.023

2.  Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

Authors:  Sherif F Nagueh; Otto A Smiseth; Christopher P Appleton; Benjamin F Byrd; Hisham Dokainish; Thor Edvardsen; Frank A Flachskampf; Thierry C Gillebert; Allan L Klein; Patrizio Lancellotti; Paolo Marino; Jae K Oh; Bogdan Alexandru Popescu; Alan D Waggoner
Journal:  J Am Soc Echocardiogr       Date:  2016-04       Impact factor: 5.251

3.  B-Type Natriuretic Peptide During Treatment With Sacubitril/Valsartan: The PARADIGM-HF Trial.

Authors:  Peder Langeland Myhre; Muthiah Vaduganathan; Brian Claggett; Milton Packer; Akshay S Desai; Jean L Rouleau; Michael R Zile; Karl Swedberg; Martin Lefkowitz; Victor Shi; John J V McMurray; Scott D Solomon
Journal:  J Am Coll Cardiol       Date:  2019-03-04       Impact factor: 24.094

4.  Sacubitril/valsartan improves both functional and echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction.

Authors:  Eugenio Roberto Cosentino; Daniela Degli Esposti; Rinaldo Miceli; Crescenzio Bentivenga; Matteo Landolfo; Arrigo Fg Cicero; Emanuela Berardi; Luca Spinardi; Gianluigi Magri; Vittorio Dugato; Claudio Borghi
Journal:  Curr Med Res Opin       Date:  2019-03       Impact factor: 2.580

5.  Impact of Sacubitril-Valsartan Treatment on Diastolic Function in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  Pere Pericas; Caterina Mas-Lladó; Maria Francisca Ramis-Barceló; Isabel Valadrón; Marta Noris Mora; Lucía Pasamar Márquez; Rosa González Colino; José Francisco Forteza Albertí; Vicente Peral Disdier; Xavier Rossello
Journal:  High Blood Press Cardiovasc Prev       Date:  2021-02-18

6.  Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction.

Authors:  Scott D Solomon; John J V McMurray; Inder S Anand; Junbo Ge; Carolyn S P Lam; Aldo P Maggioni; Felipe Martinez; Milton Packer; Marc A Pfeffer; Burkert Pieske; Margaret M Redfield; Jean L Rouleau; Dirk J van Veldhuisen; Faiez Zannad; Michael R Zile; Akshay S Desai; Brian Claggett; Pardeep S Jhund; Sergey A Boytsov; Josep Comin-Colet; John Cleland; Hans-Dirk Düngen; Eva Goncalvesova; Tzvetana Katova; Jose F Kerr Saraiva; Małgorzata Lelonek; Bela Merkely; Michele Senni; Sanjiv J Shah; Jingmin Zhou; Adel R Rizkala; Jianjian Gong; Victor C Shi; Martin P Lefkowitz
Journal:  N Engl J Med       Date:  2019-09-01       Impact factor: 91.245

7.  Angiotensin-neprilysin inhibition versus enalapril in heart failure.

Authors:  John J V McMurray; Milton Packer; Akshay S Desai; Jianjian Gong; Martin P Lefkowitz; Adel R Rizkala; Jean L Rouleau; Victor C Shi; Scott D Solomon; Karl Swedberg; Michael R Zile
Journal:  N Engl J Med       Date:  2014-08-30       Impact factor: 91.245

8.  Sacubitril/valsartan ameliorates cardiac hypertrophy and preserves diastolic function in cardiac pressure overload.

Authors:  Einar Sjaastad Nordén; Bård Andre Bendiksen; Henriette Andresen; Kaja Knudsen Bergo; Emil Knut Espe; Almira Hasic; Ida Marie Hauge-Iversen; Ioanni Veras; Rizwan I Hussain; Ivar Sjaastad; Geir Christensen; Alessandro Cataliotti
Journal:  ESC Heart Fail       Date:  2021-01-26

9.  Sacubitril/Valsartan Improves Diastolic Function But Not Skeletal Muscle Function in a Rat Model of HFpEF.

Authors:  Antje Schauer; Volker Adams; Antje Augstein; Anett Jannasch; Runa Draskowski; Virginia Kirchhoff; Keita Goto; Jeniffer Mittag; Roberta Galli; Anita Männel; Peggy Barthel; Axel Linke; Ephraim B Winzer
Journal:  Int J Mol Sci       Date:  2021-03-30       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.